Around 20% of breast cancers also express the biomarker. It remains to be seen if regulators will be amenable to a tumour-agnostic label for Enhertu, but the evidence from DESTINY-PanTumor02 is ...
Documents already unsealed by the courts reveal remarkable details about the private proposals for a wide range of hard-nosed tactics that went beyond the public efforts, like ads, op-eds and meetings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback